CG Oncology Completes Enrollment in PIVOT-006
– Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) –– One of the largest randomized...
immunotherapy
St. Baldrick’s Foundation Kicks Off Childhood Cancer Awareness Month with New ‘Send Kids’ Cancer Packing’ Initiative
Los Angeles, California--(Newsfile Corp. - September 2, 2025) - Each year, more than 15,000 families in the U.S. hear the...
Boehringer’s HERNEXEOS® approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC
Illustrative image Laboratory, Boehringer Ingelheim This press release is not intended for UK and US media. HERNEXEOS® (zongertinib tablets) has been...
Five Mothers Unite in First-Ever Collaboration to Fund $1.5 Million Groundbreaking Ewing Sarcoma Grant
Los Angeles, California--(Newsfile Corp. - August 28, 2025) - In a powerful act of unity and determination, five mothers—each having...
The International Myeloma Foundation Revives ‘Do You #kNOwMyeloma?’ for Blood Cancer Awareness Month 2025
STUDIO CITY, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- With Blood Cancer Awareness Month coming up this September, the International...
IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
LAWRENCEVILLE, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development of...
Candel Therapeutics to Participate in Upcoming Investor Conferences in September
NEEDHAM, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical...
MAIA Biotechnology Announces Publication of Interim Clinical Data on Telomere Targeting Anticancer Agent in Peer-Reviewed Journal Cells
CHICAGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company...
Fresenius Leads New EASYGEN Consortium Aimed at Decentralizing CAR-T Cell Therapy and Improving Hospital Workflows
Physicians, researchers, and partner institutions across Europe aim to deliver innovative, personalized therapies more quickly Development project focused on a...
Astrin Biosciences Appoints MIT Cancer Researcher Dr. Forest White as Distinguished Scientist to Advance Application of Proteomics for Early Cancer Detection
ST. PAUL, Minn., Aug. 26, 2025 /PRNewswire/ -- Today, Astrin Biosciences, the cancer intelligence company transforming detection and treatment via...
Adagene to Participate in Two Investor Conferences in September
SAN DIEGO and SUZHOU, China, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company...
PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer
Median Overall Survival (mOS) of 39.3 months in patients with CPS ≥ 1 – best published result with standard of...
24/7 Market News: LIXTE Targets Large, Unmet Oncology Markets
Current Clinical Trial Focus is MSS Colorectal Cancer, Ovarian Clear-Cell Carcinoma, and Soft-Tissue SarcomaDENVER, Aug. 25, 2025 (GLOBE NEWSWIRE) --...
Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation
Proprietary platform is built on one of the largest multimodal oncology datasets, including 250,000+ tumor exomes, 1 million+ plasma timepoints,...
Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation
Proprietary platform is built on one of the largest multimodal oncology datasets, including 250,000+ tumor exomes, 1 million+ plasma timepoints,...
TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference
TAMPA, Fla., Aug. 20, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel therapeutics to...
REPEAT — Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
Includes $36 million line of credit and potential $14 million private placement WARREN, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) --...
LIXTE Biotechnology Holdings Provides Corporate Update
-Completes Two Financings, Raising $6.5 Million- -Regains Compliance for Continued Listing on Nasdaq- -Announces Management Changes; Adds Two New Board...
OncoC4 Strengthens Leadership Team with Appointment of Shiniu Wei as Chief Financial Officer
ROCKVILLE, Md., Aug. 18, 2025 (GLOBE NEWSWIRE) -- OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer today...
Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis
ENX-CL-05-001 Trial: 3-months topline data - In the overall modified intention-to-treat (mITT) population, improvements across all efficacy and secondary endpoints, including...